-
Product Insights
NewBeta Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Beta Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains, a component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This deficiency leads to anemia and various complications. Beta-thalassemia is classified based on the severity of symptoms: In beta-thalassemia major (Cooley's anemia), individuals have little or no beta-globin production, leading...
-
Product Insights
NewPeripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially...
-
Product Insights
NewOcclusive Arterial Disease (OAD) – Drugs In Development, 2024
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions. Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such...
-
Product Insights
NewPeripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may...
-
Product Insights
NewClostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024
Empower your strategies with our Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or "C. diff", a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ferric Carboxymaltose in Chemotherapy Induced Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ferric Carboxymaltose in Chemotherapy Induced Anemia Drug Details: Ferric carboxymaltose (Ferinject, Injectafer, Renegy, Feryxa) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Cd19 For Lymphoma in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target Cd19 For Lymphoma in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Cd19 For Lymphoma in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vamifeport Hydrochloride in Sickle Cell Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vamifeport hydrochloride in Sickle Cell Disease Drug Details: Vamifeport (VIT-2763) is under development for...